Orchestra BioMed Holdings Inc. has announced a new infusion of $70 million in strategic capital from Ligand Pharmaceuticals and Medtronic to support its advanced cardiology programs. Under the agreement, Ligand will invest $35 million, receiving a tiered royalty on future sales of Orchestra's AVIM therapy and Virtue SAB, alongside an additional $5 million equity stake. Medtronic, in turn, will invest $10 million in equity and an additional $20 million in a promissory note convertible to prepaid revenue share, contingent on FDA approval of AVIM therapy. The collaboration will also focus on developing AVIM therapy-enabled leadless pacemakers, marking a significant step forward in Orchestra BioMed's efforts to bring innovative cardiovascular solutions to market.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。